Chemomab Therapeutics (CMMB) Change in Account Payables (2018 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Change in Account Payables came in at -$215000.0 in Q4 2023, down 148.75% YoY from $441000.0 in Q4 2022, and up 86.7% on a QoQ basis from -$1.6 million in Q3 2023.
Chemomab Therapeutics (CMMB) Change in Account Payables (2018 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 6 years of Change in Account Payables data on file, last reported at -$215000.0 in Q4 2023.
- Quarterly Change in Account Payables fell 148.75% year-over-year to -$215000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$1.2 million (down 432.95% YoY) and the FY2025 annual result came in at -$177000.0, down 251.28% from the prior year.
- Change in Account Payables grew to -$215000.0 in Q4 2023, from -$1.6 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $854000.0 in Q4 2021 to a low of -$1.6 million in Q3 2023.
- A 5-year average of $74950.0 and a median of $98000.0 in 2020 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2021 — Change in Account Payables soared 1193.94% — and 2022, when it sank 2166.67%.
- Tracing CMMB's Change in Account Payables over 5 years: stood at $163000.0 in 2019, then slumped by 59.51% to $66000.0 in 2020, then soared by 1193.94% to $854000.0 in 2021, then sank by 48.36% to $441000.0 in 2022, then plunged by 148.75% to -$215000.0 in 2023.
- The last three Change in Account Payables figures came in at -$215000.0 (Q4 2023), -$1.6 million (Q3 2023), and $130000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -215,000.00 |
| Dec 31, 2023 | -215,000.00 |
| Sep 30, 2023 | -1.62 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | 130,000.00 |
| Jun 30, 2023 | 130,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Dec 31, 2022 | 441,000.00 |
| Dec 31, 2022 | 441,000.00 |
| Sep 30, 2022 | -186,000.00 |
| Sep 30, 2022 | -186,000.00 |
| Jun 30, 2022 | -54,000.00 |
| Jun 30, 2022 | -54,000.00 |
| Mar 31, 2022 | 151,000.00 |
| Mar 31, 2022 | 151,000.00 |
| Dec 31, 2021 | 854,000.00 |
| Dec 31, 2021 | 854,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Sep 30, 2021 | 9,000.00 |